New injection aims to tackle obesity – early human trial begins

NCT ID NCT06842186

Recruiting now Disease control Sponsor: Wave Life Sciences USA, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug, WVE-007, given as a shot under the skin to help with weight loss. It includes about 296 adults who are overweight or have obesity, some with pre-diabetes or type 2 diabetes. The main goal is to check safety and how the drug moves through the body, while also looking at weight-related changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY AND OVERWEIGHT OVERWEIGHT AND OBESITY

Contacts and locations

Locations

ARENSIA Research Clinic
RECRUITING

Chisinau, MD-2025, Moldova
Arensia Clinics S.R.L.
RECRUITING

Bucharest, 011658, Romania
Parexel International Early Phase Clinical Unit
RECRUITING

Harrow, HA1 3UJ, United Kingdom
Parexel International-EPCU Baltimore
RECRUITING

Baltimore, Maryland, 21225, United States
Simbec-Orion Clinical Pharmacology
RECRUITING

Merthyr Tydfil, CF48 4DR, United Kingdom
Spitalul Clinic Judetean De Urgenta Cluj
RECRUITING

Cluj-Napoca, 400006, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.